Profile: Alimera Sciences Inc (ALIM.O)
3 Aug 2015
Alimera Sciences, Inc. (Alimera), incorporated on June 4, 2003, is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company focuses on diseases affecting the back of the eye, or retina. The Company's commercial product is ILUVIEN, which has been developed to treat diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. ILUVIEN has received marketing authorization in the United States, Austria, Belgium, the Czech Republic, Denmark, Finland, France, Germany, Ireland, Italy, Luxembourg, the Netherlands, Norway, Portugal, Spain, Sweden and the United Kingdom. In the United States, ILUVIEN is indicated for the treatment of DME in patients who have been treated with a course of corticosteroids and did not have a rise in intraocular pressure (IOP). In the EU countries, in which ILUVIEN has received marketing authorization, it is indicated for the treatment of vision impairment associated with DME considered insufficiently responsive to available therapies.
The Company's only commercial product is ILUVIEN, a long duration corticosteroid intravitreal implant for the treatment of DME. ILUVIEN is non-bioerodable and is designed to deliver sustained sub-microgram levels of fluocinolone acetonide (FAc) at an initial rate of 0.25 micrograms per day and last 36 months. ILUVIEN is inserted in the back of the patient's eye in a non-surgical procedure using a sterile preloaded applicator (the ILUVIEN applicator) employing a 25-gauge needle, which allows for a self-sealing wound. This procedure is similar to that commonly employed by retinal specialists in the administration of other intravitreal therapies. In approved European countries, the procedure is performed in a hospital or private clinic setting. In the United States, the non-surgical procedure is performed in the retinal specialist's office.
ILUVIEN consists of a tiny polyimide tube with a permeable membrane cap on one end and an impermeable silicone cap on the other end that is filled with 190 micrograms of FAc in a polyvinyl alcohol matrix. Based on the Company's analysis of the final clinical readout from its FAME Study through month 36, it appears that ILUVIEN mitigates the incidence of steroid-induced IOP elevations associated with the intraocular use of corticosteroids, specifically Retisert.
The Company competes with Ophthotech Corporation, Ampio Pharmaceuticals and pSivida.
Alimera Sciences Inc
6120 Windward Pkwy Ste 290
ALPHARETTA GA 30005-8897